AmpliPhi swallows SPS to expand bacteriophage breadth
This article was originally published in Scrip
Executive Summary
Two companies specialising in bacteriophage technologies are to join forces as AmpliPhi, which has operations in the UK and US, prepares to acquire Sydney, Australia-based Special Phage Services (SPS). The all-share transaction will create "the world's leading anti-infective company focused on bacteriophage-based therapies", they claim.
You may also be interested in...
AmpliPhi Advances Phage In Clinic To Address Microbial Infections
Emerging Company Profile: Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi has made progress in Phase I studies for its lead program. CEO Scott Salka explains to Mike Ward how he is looking to secure sufficient capital to support the Phase II development of AmpliPhi's lead program against chronic rhinosinusitis while advancing other product candidates.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.